Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$22.22 - $39.12 $6.92 Million - $12.2 Million
-311,615 Reduced 29.96%
728,385 $18.3 Million
Q3 2021

Nov 15, 2021

SELL
$13.18 - $19.83 $4.78 Million - $7.2 Million
-363,000 Reduced 25.87%
1,040,000 $17.8 Million
Q2 2021

Aug 16, 2021

BUY
$9.59 - $50.88 $8.08 Million - $42.9 Million
843,000 Added 150.54%
1,403,000 $18.8 Million
Q1 2021

May 14, 2021

BUY
$49.53 - $68.4 $8.57 Million - $11.8 Million
173,000 Added 44.7%
560,000 $28.7 Million
Q4 2020

Feb 16, 2021

BUY
$47.25 - $65.16 $4.25 Million - $5.86 Million
90,000 Added 30.3%
387,000 $24 Million
Q3 2020

Nov 13, 2020

BUY
$46.35 - $61.69 $5.65 Million - $7.53 Million
122,000 Added 69.71%
297,000 $16.3 Million
Q2 2020

Aug 14, 2020

BUY
$38.58 - $65.07 $6.75 Million - $11.4 Million
175,000 New
175,000 $10.1 Million

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Eventide Asset Management, LLC Portfolio

Follow Eventide Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.